In a groundbreaking move, President Joe Biden's proposal to reclassify marijuana to Schedule 3 under the Controlled Substances Act signals a potential shift away from decades of what many consider to be failed drug policies. This shift not only promises opportunities for advancement in science and business but also raises questions about the future of other substances, such as psilocybin, the psychoactive compound found in magic mushrooms.
Despite the increasing recognition of psilocybin's therapeutic potential and its low risk of fatal overdose, current federal classification places it alongside substances as dangerous as fentanyl, a key contributor to the nation's overdose crisis.
The latest research into psilocybin therapy as a treatment for tobacco addiction has yielded promising results eskymaks/Depositphotos
Psilocybin mushrooms, like marijuana, are categorized as Schedule 1 drugs under the Controlled Substances Act, presenting significant barriers to research on their safety and potential benefits. This paradox, familiar to those advocating for marijuana reform, highlights the need for relaxed restrictions to facilitate scientific exploration.
Could psilocybin be next in line for reconsideration after marijuana? According to Andrew Livingston, Director of Economics and Research at the Vicente law firm based in Denver, the process may not mirror that of marijuana's rescheduling. While the parallels between psychedelic substances and cannabis are evident, their regulatory landscapes differ significantly, shaping the approach to reform on both state and federal levels.
The burgeoning field of legal psychedelics has seen mushrooms labeled as "breakthrough therapy" for conditions like major depressive disorder and treatment-resistant depression by the FDA. Institutions like Johns Hopkins University are exploring psilocybin's potential in treating various mental health disorders, with funding primarily sourced from philanthropy rather than federal grants.
State-level initiatives have also played a pivotal role in advancing psychedelic therapy. Oregon legalized psilocybin for licensed therapeutic sessions in 2023, followed by Colorado's scheduled implementation in 2025. Unlike cannabis, which has seen consumer products legalized, psychedelic therapy remains a supervised practice, emphasizing safety and controlled administration.
Despite strides made at the state level, federal reform lags behind. While marijuana legalization has gained traction in 40 states and Washington DC, predictions suggest it may take until 2034-2037 for a majority of states to legalize psychedelics.
The path to federal reform for psychedelics, however, remains unclear. Unlike marijuana, which benefited from data gleaned from state-regulated programs, psychedelics lack a comparable demand and market structure. Livingston underscores the importance of crafting policies that ensure economic viability while fostering healthcare practitioner and patient participation to generate the necessary data for federal reconsideration.
In essence, while President Biden's proposal marks a significant step towards drug policy reform, the journey for substances like psilocybin towards federal rescheduling requires nuanced considerations tailored to the unique landscape of psychedelic therapy.
Sources: Chris Roberts, “Murshroom joe How President Biden Could reschedule pilocyibin like marijuana”, MJBizDaily, 03/22/2024, https://mjbizdaily.com/how-president-biden-could-reschedule-psilocybin-mushrooms/, Accssed 03/22/24
Comentarios